Capricor Shares Rise as FDA Lifts Duchenne Cell Therapy Rejection
Capricor Therapeutics’ deramiocel was rejected in July 2025, potentially caught between Nicole Verdun, a former top biologics regulator at the FDA, and Vinay Prasad, director of the Center for Biologics Evaluation and Research.
Capricor Shares Rise as FDA Lifts Duchenne Cell Therapy Rejection Read More »
